HongKong:1916701D

Asia Pacific Cell & Gene Research Growing 50% Faster than ROW

Retrieved on: 
금요일, 2월 3, 2023
AU, Degenerative disease, Gene, ROW, The Sporting News Minor League Player of the Year Award, Lymphatic system, Cros, CNS, Infection, Patent, Research, Acquisition, European, Investment, Cell, Fine chemical, Agriculture

SYDNEY, AU, Feb 3, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW.

Key Points: 
  • SYDNEY, AU, Feb 3, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW.
  • Novotech, which has extensive experience in cell & gene therapy clinical trials, is sponsoring the 6th Annual Cell And Gene Therapy Innovation Summit in Berlin, Germany (15-16 February 2023).
  • The latest data shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region.
  • The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021.

Novotech Acquires European CRO, Strengthens Global Operations

Retrieved on: 
목요일, 1월 12, 2023
Gene, Cros, Culture, Friends, Frost, Acquisition, Cell, Fine chemical, European

Novotech CEO Dr. John Moller said: "This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs.

Key Points: 
  • Novotech CEO Dr. John Moller said: "This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs.
  • EastHORN and Novotech have been working together for many years and we share a culture of clinical excellence in biotech drug development.
  • EastHORN has been working closely with Novotech for over a decade now and have many friends within the Novotech team.
  • In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.

Novotech Acquires US-based Drug Development Consulting Firm, CBR International

Retrieved on: 
목요일, 1월 12, 2023
IND, Gene, CBR, Cros, Biotechnology, IDE, FDA, US FDA, Drug development, NDA, BLA, Bureau of Oceans and International Environmental and Scientific Affairs, Frost, Acquisition, CGMP, Toxicology, Cell, Fine chemical, Medical device, Pharmaceutical industry

CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services.

Key Points: 
  • CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services.
  • Novotech CEO Dr. John Moller said: "CBR will provide decades of FDA regulatory experience for our biotech clients.
  • Navigating novel product development and achieving multiple approvals has built our expertise to support the complex development needs of clients worldwide which will now support Novotech clients.
  • We look forward to working with Novotech clients to support their drug development programs in the US and globally.